XIPERE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XIPERE (XIPERE).
Triamcinolone acetonide is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and stabilizing lysosomal membranes. It also decreases vascular permeability and inhibits cytokine release.
| Metabolism | Primarily metabolized in the liver via CYP3A4. |
| Excretion | XIPERE (triamcinolone acetonide injectable suspension) is primarily eliminated via hepatic metabolism and subsequent renal excretion of metabolites. Approximately 40% of the dose is excreted renally as metabolites, with less than 5% as unchanged drug. Biliary/fecal excretion accounts for about 60% of the dose, mainly as metabolites. |
| Half-life | The terminal elimination half-life of triamcinolone acetonide following suprachoroidal administration is approximately 18 hours. This short half-life allows for sustained local effect with minimal systemic accumulation. |
| Protein binding | Triamcinolone acetonide is approximately 68% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The volume of distribution for triamcinolone acetonide is approximately 1.4 L/kg, indicating extensive tissue distribution, consistent with its lipophilic nature. |
| Bioavailability | Following suprachoroidal injection, XIPERE provides local delivery with negligible systemic bioavailability. Systemic absorption is minimal, resulting in low plasma concentrations. No oral bioavailability data are applicable as it is not administered orally. |
| Onset of Action | Clinical effect (reduction in macular edema) is observed within 2 to 4 weeks following a single suprachoroidal injection of XIPERE. |
| Duration of Action | The duration of therapeutic effect is approximately 3 to 6 months after a single suprachoroidal injection. Repeat dosing may be considered based on clinical response. |
| Molecular Weight | 434.5 |
The recommended dose is 0.1 mL (containing 0.16 mg triamcinolone acetonide injectable suspension) administered by suprachoroidal injection to the affected eye(s) once every 3 months (every 12 weeks).
| Dosage form | SUSPENSION |
| Renal impairment | No dosage adjustment is required for patients with renal impairment. |
| Liver impairment | No formal studies have been conducted; however, triamcinolone acetonide is primarily metabolized by the liver. Use with caution in patients with severe hepatic impairment (Child-Pugh class C). |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. |
| Geriatric use | No specific dosage adjustment is recommended for geriatric patients; however, consider the increased frequency of comorbidities and concomitant medications. |
| 1st trimester | No adequate human data; animal studies show risk. Corticosteroids may cause cleft palate in animal studies. Use only if benefit outweighs risk. |
| 2nd trimester | Same as T1; consider risk of fetal growth restriction and adrenal suppression with prolonged use. |
| 3rd trimester | Risk of neonatal adrenal suppression if used near term. Avoid unless essential. |
Clinical note
Comprehensive clinical and safety monograph for XIPERE (XIPERE).
| Placental transfer | Triamcinolone acetonide (active ingredient) crosses the placenta; metabolism by placental 11β-HSD2 limits fetal exposure. Fetal levels are approximately 10-50% of maternal levels. |
| Breastfeeding | Systemic absorption after ocular injection is minimal; however, corticosteroids are excreted in breast milk in small amounts. Risk of adrenal suppression in infant is low. Caution advised. |
■ FDA Black Box Warning
No FDA black box warning reported.
| Serious Effects |
Hypersensitivity to triamcinolone acetonide or any excipientActive ocular or periocular infections (including viral, bacterial, fungal, mycobacterial)Glaucoma with uncontrolled intraocular pressurePost-surgical or traumatic conditions where risk of infection is high
| Precautions | Increased intraocular pressure (IOP) requiring monitoring, Cataract formation, Ocular infections (including fungal, bacterial, viral), Posterior subcapsular cataract, Glaucoma progression, Systemic corticosteroid effects (e.g., adrenal suppression) with frequent use |
| Food/Dietary | None known. No dietary restrictions are required with XIPERE administration. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | XIPERE (triamcinolone acetonide injectable suspension) is a corticosteroid. Systemic corticosteroids are associated with increased risk of orofacial clefts (first trimester) and intrauterine growth restriction (second/third trimester). Intraocular administration minimizes systemic exposure, but no adequate human data exist; risk cannot be excluded. |
| Fetal Monitoring | Monitor intraocular pressure (IOP) regularly due to steroid-induced glaucoma. Assess for cataract formation. Fetal monitoring: ultrasound for growth restriction if systemic exposure suspected. No specific fetal monitoring required with standard ophthalmic use. |
| Fertility Effects | No human data. Animal studies with systemic corticosteroids may impair fertility, but relevance to intraocular administration is unknown. No known effect on fertility with single dose. |
| Clinical Pearls |
| XIPERE (triamcinolone acetonide injectable suspension) is a corticosteroid for suprachoroidal space administration to treat macular edema associated with uveitis. Use a 27-gauge needle and inject slowly (0.1 mL over 2-3 seconds) to minimize reflux. Contraindicated in active ocular infections, glaucoma with cup-to-disc ratio >0.8, or ruptured globe. Monitor intraocular pressure post-injection; consider prophylactic IOP-lowering agents in high-risk patients. Avoid re-treatment within 12 weeks; cumulative dose should not exceed 4 mg per eye per year. |
| Patient Advice | This medication is injected into the back part of your eye to reduce swelling and inflammation. · You may experience temporary blurred vision, floaters, or eye discomfort after the injection. · Report any sudden vision loss, eye pain, or signs of infection (redness, discharge) immediately. · Do not rub or press on the treated eye for at least 24 hours after the injection. · Avoid strenuous activities or heavy lifting for a few days to prevent increased eye pressure. · Attend all follow-up appointments to monitor eye pressure and response to treatment. · Tell your doctor if you have a history of glaucoma, herpes simplex, or recent eye surgery. |